Get notified when SMNR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Risk Profile Improvements

  • Controlled Company (new) — Scilex controls 82% of voting power, giving public shareholders minimal influence over corporate decisions.
  • Material Weakness (new) — Material weaknesses in internal control over financial reporting create risk of undetected material misstatements.
  • Single-Product Dependence (new) — SP-102 is the only product candidate; entire business depends on this single asset reaching approval and commercialization.
OTC: SMNR Semnur Pharmaceuticals, Inc. 424B3

Semnur Pharmaceuticals selling securityholders offer up to 12.85M warrants; company receives no proceeds from resale

Filed December 29, 2025 · ~2 min read

IPO filing cluster

Same offering
  1. S-1 Oct 21, 2025 Semnur Pharmaceuticals secondary offering by selling stockholders; company receives no proceeds EDGAR →
  2. S-1/A Dec 19, 2025 Semnur starts 2nd Phase 3 study as cash falls to $0.1M; $154M net loss driven by non-cash charges EDGAR →
  3. 424B3 Dec 29, 2025 This filing EDGAR →
  4. 424B3 Jun 15, 2026 No report yet EDGAR →
  5. 8-K Jun 25, 2026 No report yet EDGAR →

Key Changes

  • high

    Secondary offering by selling securityholders of up to 12,850,000 warrants and shares. Semnur receives no proceeds from these sales; all proceeds go to selling securityholders including parent company Scilex (which controls 82% of voting power), former officers/directors who departed September 2025, and IPO underwriters.

    The Offering verify on EDGAR →
  • high

    Company may receive up to $100.7M if all warrants are exercised for cash (not guaranteed), to be used for working capital and general corporate purposes including R&D, clinical trials, and potential debt repayment.

    Use of Proceeds verify on EDGAR →
  • high

    Semnur is developing SP-102, a non-opioid injectable corticosteroid gel for sciatica with FDA fast track designation. FDA required a second confirmatory Phase 3 trial (CLEAR-2, ~700 patients) after rejecting the single CLEAR-1 trial as insufficient; commercial launch now targeted for second half of 2027.

    Business view on EDGAR →

5 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FRVO 10-Q) is open in full — no account needed.

Partner

Trade SMNR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · Jun 26, 2026 5:31 PM